GH Research PLC Board of Directors

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Mr. Florian Schonharting M.Sc. (Econ)

Mr. Florian Schonharting M.Sc. (Econ)

Co-Founder & Non-Executive Chairman of the Board

Mr. Magnus Halle

Mr. Magnus Halle

Co-Founder & MD of Ireland

Dr. Velichka Valcheva M.D.

Dr. Velichka Valcheva M.D.

Chief Executive Officer

Ms. Julie Ryan F.C.A.

Ms. Julie Ryan F.C.A.

Vice President of Finance

Mr. Aaron Cameron M.B.A.

Mr. Aaron Cameron M.B.A.

Chief Operating Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.